Additionally, this cell type-specific effect could be explained by mutations on the NR4A1-downstream RE or the TAD boundaries where this gene is located on the pancreatic cancer cells, but not on the breast cancer cells, following the enhancer retargeting process observed on the ZCCHC7 gene during B cell lymphoma progression [42]. The gene discussed is NR4A1; the disease is familial pancreatic carcinoma.